FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game
Merck just got a leg up in its quest to leapfrog Pfizer’s best-selling pneumococcal conjugate vaccine Prevnar 13. The FDA is providing its breakthrough drug designation for the pharma giant’s late-stage efforts on V114, adding it to the VIP list for drugs tapped for swift handling.
V114’s claim to fame is that it does Pfizer’s Prevnar 13 two better in terms of the pneumococcus strains covered.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
